Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Tamoxifen, a drug commonly used to treat breast cancer, may also help reduce the risk of death from lung cancer, said a study published in the US peer-reviewed journal Cancer on Monday.
Tamoxifen works by blocking estrogen. Previous studies have shown that women undergoing hormone replacement therapy to boost estrogen during menopause showed an increased risk of dying from lung cancer.
Based on the hypothesis that blocking estrogen might also cut lung cancer death risk, researchers examined data from 6,655 women diagnosed with breast cancer between 1980 and 2003 in Switzerland's Geneva Cancer Registry.
Close to half of those women, 3,066 (46 percent), were given anti-estrogen drugs.
The registry's Elisabetta Rapiti, lead author of the study in Cancer, followed all those subjects until December 2007 and looked at how many developed lung cancer and how many died from lung cancer.
Rapiti found that among those taking anti-estrogen drugs, there were 87 percent fewer deaths from lung cancer when compared to the general population.
When she looked simply at how many women in the study were diagnosed with lung cancer, she found no significant difference between those taking anti-estrogen therapy and those who were not.
"Our results support the hypothesis that there is a hormonal influence on lung cancer which has been suggested by findings such as the presence of estrogen and progesterone receptors in a substantial proportion of lung cancers," said Rapiti.
"If prospective studies confirm our results and find that anti-estrogen agents improve lung cancer outcomes, this could have substantial implications for clinical practice," she added.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments